MedTrace Logo

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2023-08-01

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.

Conditions

Interventions

DRUG

CBP-201

CBP-201 subcutaneous(SC) injection.

DRUG

placebo

subcutaneous(SC) injection

Sponsors & Collaborators

  • Connect Biopharm LLC

    lead INDUSTRY

Principal Investigators

  • Suzhou Connect · Connect Biopharm LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2021-07-28
Completion
2021-09-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04444752 on ClinicalTrials.gov